The effectiveness of rehabilitation in vulvovaginal atrophy

Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients wi...

Full description

Saved in:
Bibliographic Details
Published in:Farmakoèkonomika (Moskva. Online) Vol. 17; no. 2; pp. 200 - 211
Main Authors: Ampilogova, D. М., Solopova, А. G., Blinov, D. V., Ivanov, А. Е., Khlopkova, S. V., Bykovshchenko, G. К.
Format: Journal Article
Language:English
Russian
Published: IRBIS LLC 01-08-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months. Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3 rd month of follow-up. No adverse events were registered. Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients.
AbstractList Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months.Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3rd month of follow-up. No adverse events were registered.Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients.
Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control group included 70 women without VVA. Patients with VVA were distributed into groups receiving complex “active” rehabilitation (surgical menopause: group 1A, natural menopause: group 2A) and “passive” rehabilitation (surgical menopause: group 1B, natural menopause: group 2B). Body mass index (BMI), vaginal pH, carbohydrate profile with calculation of insulin resistance index (HOMA-IR), inflammatory markers leptin, interleukin-6, tumour necrosis factor alpha, serum magnesium, and safety profile with evaluation of adverse events related to rehabilitation measures were assessed over 24 months. Results. BMI decreased significantly in groups 1A and 2A. Vaginal pH at 1-year follow-up decreased in groups 1A and 2A, but increased in groups 2A and 2B. BMI was higher than normal in all patients with VVA, as well as in the control group, demonstrating preobesity (groups 1A, 2A, control group) or first-degree obesity (initially in group 1B and throughout follow-up in group 2B). HOMA-IR initially reflected postoperative insulin resistance in groups 1A and 2A, but in those receiving complex “active” rehabilitation the dynamics of its reduction was the most pronounced. The concentration of inflammatory markers was initially increased compared to the control group and decreased over time in groups 1A and 1B, but only leptin levels reached the control group values by the end of the study. Serum concentration of magnesium levels was 0.71±0.12 mmol/l in group 1A, 0.71±0.10 mmol/l in group 2A, 0.76±0.08 mmol/l in group 1B, 0.72±0.17 mmol/l in group 2B (magnesium deficiency). When organic magnesium salts in combination with pyridoxine were supplemented in groups 1A and 1B, serum magnesium levels were restored to normal from the 3 rd month of follow-up. No adverse events were registered. Conclusion. The personalised programme of complex “active” rehabilitation in patients with VVA is more effective than “passive” rehabilitation with comparable safety profile. Its implementation into routine practice will contribute to the improvement of the quality of health care for such patients.
Author Ivanov, А. Е.
Blinov, D. V.
Khlopkova, S. V.
Ampilogova, D. М.
Solopova, А. G.
Bykovshchenko, G. К.
Author_xml – sequence: 1
  givenname: D. М.
  orcidid: 0000-0002-3509-9501
  surname: Ampilogova
  fullname: Ampilogova, D. М.
  organization: City Clinical Hospital No. 52
– sequence: 2
  givenname: А. G.
  orcidid: 0000-0002-7456-2386
  surname: Solopova
  fullname: Solopova, А. G.
  organization: Sechenov University
– sequence: 3
  givenname: D. V.
  orcidid: 0000-0002-3367-9844
  surname: Blinov
  fullname: Blinov, D. V.
  organization: Sechenov University; Institute for Preventive and Social Medicine; Moscow Haass Medical Social Institute
– sequence: 4
  givenname: А. Е.
  orcidid: 0000-0003-1115-3144
  surname: Ivanov
  fullname: Ivanov, А. Е.
  organization: Yudin City Clinical Hospital
– sequence: 5
  givenname: S. V.
  orcidid: 0000-0003-2918-9401
  surname: Khlopkova
  fullname: Khlopkova, S. V.
  organization: Vorokhobov City Clinical Hospital No. 67
– sequence: 6
  givenname: G. К.
  surname: Bykovshchenko
  fullname: Bykovshchenko, G. К.
  organization: Sechenov University
BookMark eNpd0M1KAzEQwPEgCtaPd9gHcOtkk90keBI_CwUveg6zycTGbjeSXQt9e1tbevCUIQz_gd8FO-1TT4zdcJhypaS5rUBBKQ2Y24B5hctEy9SnVVzitIJKTqtan7DJYUuI0-MM5pxdD0NsQUolGqWrCbt7X1BBIZAb45p6GoYihSLTAtvYxRHHmPoi9sX6p1unNX7GHrsCx5y-F5srdhawG-j68F6yj-en94fXcv72Mnu4n5eOa6PLOvjGQ-Ma3xoyovZCE0BVByNVcJpCK2WrWk_gBHKvKnAVAveBSDg0jbhks33XJ_yy3zmuMG9swmj_PlL-tJjH6DqyGrwxPmhVGyclJ-R1gJq3fntetADb1uO-5XIahkzh2ONg_3ztTsvutOx_X7vztVtf8QuM7HhC
Cites_doi 10.17749/2077-8333/epi.par.con.2022.115
10.17749/2313-7347/ob.gyn.rep.2022.344
10.1007/s10549-021-06226-3
10.26442/20795696.2020.6.200485
10.1097/GME.0000000000001496
10.25207/1608-6228-2023-30-5-41-53
10.17749/2313-7347/ob.gyn.rep.2022.318
10.17749/2313-7347/ob.gyn.rep.2023.426
10.26442/20795696.2022.4.201792
10.1186/s12941-020-0347-4
10.55453/rjmm.2022.125.1.7
10.1016/S0029-7844(96)00447-4
10.1097/GME.0000000000002195
10.1080/09513590.2018.1563883
10.17749/2313-7347/ob.gyn.rep.2023.392
10.1016/j.jcma.2011.08.014
10.17749/2313-7347/ob.gyn.rep.2022.371
10.17749/2077-8333/epi.par.con.2023.168
10.1016/j.ejogrb.2022.08.012
10.3390/medicina58060770
10.17749/2313-7347/ob.gyn.rep.2022.345
10.1080/01443615.2020.1832973
10.17749/2313-7347/ob.gyn.rep.2023.391
10.17749/2070-4909/farmakoekonomika.2022.159
10.17749/2313-7347/ob.gyn.rep.2022.283
10.6118/jmm.2014.20.3.104
10.17749/2313-7347/ob.gyn.rep.2023.461
10.1080/13697137.2023.2225766
10.17749/2313-7347/ob.gyn.rep.2024.512
10.1097/AOG.0000000000003729
10.14341/7637
10.1080/13697137.2018.1446930
10.1016/j.maturitas.2023.03.007
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.17749/2070-4909/farmakoekonomika.2024.258
DatabaseName CrossRef
Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 2070-4933
EndPage 211
ExternalDocumentID oai_doaj_org_article_80d99df8759c441ea15f051bd6c63b00
10_17749_2070_4909_farmakoekonomika_2024_258
GroupedDBID 642
AAFWJ
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
GROUPED_DOAJ
ID FETCH-LOGICAL-c1898-5fd6d06c6db9e935d38e0025f947fc8efb44b7bde0c3a1d720c2a01dfee3ca963
IEDL.DBID DOA
ISSN 2070-4909
IngestDate Mon Oct 21 19:39:16 EDT 2024
Fri Nov 22 02:36:09 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
Russian
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1898-5fd6d06c6db9e935d38e0025f947fc8efb44b7bde0c3a1d720c2a01dfee3ca963
ORCID 0000-0003-2918-9401
0000-0002-7456-2386
0000-0002-3509-9501
0000-0003-1115-3144
0000-0002-3367-9844
OpenAccessLink https://doaj.org/article/80d99df8759c441ea15f051bd6c63b00
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_80d99df8759c441ea15f051bd6c63b00
crossref_primary_10_17749_2070_4909_farmakoekonomika_2024_258
PublicationCentury 2000
PublicationDate 2024-08-01
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-01
  day: 01
PublicationDecade 2020
PublicationTitle Farmakoèkonomika (Moskva. Online)
PublicationYear 2024
Publisher IRBIS LLC
Publisher_xml – name: IRBIS LLC
References ref13
ref35
ref12
ref34
ref15
ref14
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref25
  doi: 10.17749/2077-8333/epi.par.con.2022.115
– ident: ref29
  doi: 10.17749/2313-7347/ob.gyn.rep.2022.344
– ident: ref35
  doi: 10.1007/s10549-021-06226-3
– ident: ref20
– ident: ref12
  doi: 10.26442/20795696.2020.6.200485
– ident: ref3
  doi: 10.1097/GME.0000000000001496
– ident: ref24
  doi: 10.25207/1608-6228-2023-30-5-41-53
– ident: ref26
  doi: 10.17749/2313-7347/ob.gyn.rep.2022.318
– ident: ref32
  doi: 10.17749/2313-7347/ob.gyn.rep.2023.426
– ident: ref22
– ident: ref6
  doi: 10.26442/20795696.2022.4.201792
– ident: ref8
  doi: 10.1186/s12941-020-0347-4
– ident: ref9
  doi: 10.55453/rjmm.2022.125.1.7
– ident: ref23
  doi: 10.1016/S0029-7844(96)00447-4
– ident: ref14
  doi: 10.1097/GME.0000000000002195
– ident: ref2
  doi: 10.1080/09513590.2018.1563883
– ident: ref31
  doi: 10.17749/2313-7347/ob.gyn.rep.2023.392
– ident: ref21
  doi: 10.1016/j.jcma.2011.08.014
– ident: ref16
  doi: 10.17749/2313-7347/ob.gyn.rep.2022.371
– ident: ref33
  doi: 10.17749/2077-8333/epi.par.con.2023.168
– ident: ref11
  doi: 10.1016/j.ejogrb.2022.08.012
– ident: ref7
  doi: 10.3390/medicina58060770
– ident: ref28
  doi: 10.17749/2313-7347/ob.gyn.rep.2022.345
– ident: ref5
  doi: 10.1080/01443615.2020.1832973
– ident: ref30
  doi: 10.17749/2313-7347/ob.gyn.rep.2023.391
– ident: ref15
  doi: 10.17749/2070-4909/farmakoekonomika.2022.159
– ident: ref27
  doi: 10.17749/2313-7347/ob.gyn.rep.2022.283
– ident: ref19
  doi: 10.6118/jmm.2014.20.3.104
– ident: ref34
  doi: 10.17749/2313-7347/ob.gyn.rep.2023.461
– ident: ref13
  doi: 10.1080/13697137.2023.2225766
– ident: ref17
  doi: 10.17749/2313-7347/ob.gyn.rep.2024.512
– ident: ref4
  doi: 10.1097/AOG.0000000000003729
– ident: ref18
  doi: 10.14341/7637
– ident: ref1
  doi: 10.1080/13697137.2018.1446930
– ident: ref10
  doi: 10.1016/j.maturitas.2023.03.007
SSID ssib044736782
ssj0002243826
ssib047418763
ssib053664050
Score 2.3149545
Snippet Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA). Material and methods. The study...
Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).Material and methods. The study...
SourceID doaj
crossref
SourceType Open Website
Aggregation Database
StartPage 200
SubjectTerms anxiety
depression
genitourinary syndrome of menopause
gsm
magnesium deficiency
qol
quality of life
rehabilitation
sexual dysfunction
vulvar atrophy
vulvovaginal atrophy
vva
Title The effectiveness of rehabilitation in vulvovaginal atrophy
URI https://doaj.org/article/80d99df8759c441ea15f051bd6c63b00
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7agwgiPrG-yMGja7NJNpsgHny09ORFBW9h8wKpdKXa_n5ndmutXrx4DeySfPkyMxky3xBy5pxR3nE4SCKpTKZcZ07pmAWtnWAV96XB4uThQ3n_rO_6KJOzaPWFb8JaeeAWuJ5mwZiQIKw2Hlx3rPIiAZFcUF4J4ExjfZlaukwBk6QshVrSaZeo0VJ-C00VQimIVNgiGwOOTOimNxuHM5BJw8waOUeLAuGR6S0GewkTzaM6jpqq4REqF3F5wbFj_JJfW5L_b_zUYItszgNMet0ubJusTKY7ZKPNztG26GiXXAI7aPuUY27taJ3o5IdqN30Z09n0dVbPqqZ1FsWsOWzKHnka9B9vh9m8jULmc210VqSgAgO4gjPRiCIIHTHUSUaWyeuYnJSudCEyL6o8lJx5XrE8pBiFr-CA7pPOuB7HA0KlliHxisOWNrI8DmZahiLKxA3YBt8lV18g2LdWLcPiLQNBtAiiRRDtbxAtgmgBxC65QeQW36L2dTMAjLBzRti_GHH4Hz85Ius4qfap3zHpfEym8YSsvofpacO0Tyu60Xg
link.rule.ids 315,782,786,866,2106,27933,27934
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effectiveness+of+rehabilitation+in+vulvovaginal+atrophy&rft.jtitle=Farmako%C3%A8konomika+%28Moskva.+Online%29&rft.au=Ampilogova%2C+D.+%D0%9C.&rft.au=Solopova%2C+%D0%90.+G.&rft.au=Blinov%2C+D.+V.&rft.au=Ivanov%2C+%D0%90.+%D0%95.&rft.date=2024-08-01&rft.issn=2070-4909&rft.eissn=2070-4933&rft.volume=17&rft.issue=2&rft.spage=200&rft.epage=211&rft_id=info:doi/10.17749%2F2070-4909%2Ffarmakoekonomika.2024.258&rft.externalDBID=n%2Fa&rft.externalDocID=10_17749_2070_4909_farmakoekonomika_2024_258
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2070-4909&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2070-4909&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2070-4909&client=summon